Procysbi® (cysteamine bitartrate) – Expanded indication
January 5, 2018 - Horizon Pharma announced the FDA approval of Procysbi (cysteamine bitartrate), for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Download PDF
